Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announced that the US Patent Office has granted the company a patent (United States Patent Application Number: 16/892,369) for its artificial intelligence (AI)-powered technology for the non-invasive detection of impairment caused by alcohol and/or cannabis.
The patented technology uses multispectral imaging and speech analysis to identify and extract features from an individual, allowing the technology to determine whether the individual is exhibiting signs associated with impairment. The technology is part of the company's Fit for Duty screening solutions, which provide contactless and bias-free screening for impairment, extreme fatigue, and infectious diseases.
"The patent grant for our impairment screening technology is yet another milestone for Predictmedix," said Dr Rahul Kushwah, chief operating officer at Predictmedix in a statement. "Our proprietary technology has the potential to revolutionize the way that businesses and organizations screen for impairment.
READ: Predictmedix announces production of AI-powered mobile application to detect impairment from alcohol and cannabis
Kushwah added that the company has a lot of “exciting” opportunities in its pipeline and that providing proven, accurate solutions to combat impairment is a “top priority” for Predictmedix.
“With the grant of this patent, we have strengthened our position as a leader in the health screening industry and we are excited to continue to expand our offerings and make a positive impact on workplaces and organizations around the world," he said.
The Safe Entry is a walk-thru system which uses a multispectral imaging camera and AI computing to gather key physiological information in just 2-3 seconds to determine an individual's physiological state. Unlike urine and breathalyzer tests, Safe Entry is contactless, which means no biological fluids are taken. Safe Entry is powered by AI and machine learning (ML) algorithms, which give individuals a fair and accurate assessment of their physiological state.
Predictmedix pointed out that the global workplace safety market was valued at $12.8 billion in 2021, and is projected to reach $39 billion by 2031, growing at a compound annual rate (CAGR) of 12.2% from 2022 to 2031, while the drug screening market size is expected to grow at a CAGR of 15.97% from 2022 to 2029, reaching nearly $22.24 billion.
Predictmedix is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Safe Entry Stations - powered by a proprietary AI - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses.
Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.
Contact the author at jon.hopkins@proactiveinvestors.com